ERBB3 and breast carcinoma: In HER2 + breast cancer, drug exposure can lead to HER3 mediated compensatory signaling, leading to a 2-log fold increase in signaling output, far exceeding the therapeutic index of drugs acting on the HER2 active kinase domain [13].